

CONTENTS

	Page No
PREFACE	I-VII
 Chapter 1: Importance of development and validation of analytical methods for the determination of related components in pharmaceutical compounds using chromatography technique.	
1.1 Introduction on development of analytical methods for the determination of related components in pharmaceutical compounds	1-2
1.2 Sources of impurities in pharmaceutical substances.	2-9
1.3 Requirement for control of impurities.	9-17
1.4 Control of Organic Impurities.	17-19
1.5 Stability testing of New Drug substances and Drug Products.	19-25
1.6 Stress testing route to the development of stability-indicating analytical methods (SIAMs).	25-33
1.7 Techniques employed in literature reports for the development of Stability-indicating Analytical Methods (SIAMs).	33-48
1.8 Scope and Objectives of research work.	48-59
 Chapter 2 :	
2.1 Introduction of Nateglinide	60-61
2.2 Part-A: Development and Validation of a novel LC method for determination of related components in Nateglinide	61-119
2.3 Analysis of Nateglinide drug substance stability samples	119-120
2.4 Summary and Conclusions	120-123

CONTENTS (Contd.,)

	Page No
Chapter 2: (Contd.,)	
2.5 Part-B: A validated reverse phase chiral liquid chromatographic method for the enantiomeric purity determination of Nateglinide in bulk drug samples and pharmaceutical dosage forms.	124- 162
2.6 Stability study of Nateglinide bulk drug as per ICH Conditions	163
2.7 Summary and Conclusion	164-168
Chapter 3 : Development and validation of a new analytical method for the determination of related components and assay of Ranolazine in bulk drug and pharmaceutical dosage forms by LC	
3.1 Introduction of Ranolazine and survey of analytical methods	172-174
3.2 Development and validation of a novel HPLC method for the determination of Related Components in Ranolazine.	175-231
3.3 Analysis of Ranolazine drug substance stability samples	231-233
3.4 Summary and Conclusions	234-237
Chapter 4: Development and Validation of a New LC Method for Analysis of Brimonidine Tartrate and Related Compounds	
4.1 Introduction of Brimonidine Tartrate and survey of analytical methods	238-241
4.2 Development of a novel HPLC method for the determination of Related Components in Brimonidine Tartrate	241-298
4.3 Analysis of Brimonidine tartrate drug substance stability samples	298-300
4.4 Summary and Conclusions.	301-303

CONTENTS (Contd.,)

Page No

Chapter 5: Development and Validation of a New Analytical Method for the Determination of Related Components in Tolterodine Tartarate Using LC

5.1	Introduction of Tolterodine tartrate and survey of analytical methods	304-307
5.2	Development and validation of a novel HPLC method for the determination of Related Components in Tolterodine Tartrate	307-369
5.3	Analysis of Tolterodine tartrate drug substance stability samples	370-372
5.4	Summary and Conclusions.	373-376

Chapter-6: LC Separation of para and meta Isomers of Zafirlukast in Bulk Drug Samples and Pharmaceutical Dosage Forms Using a Ca Chiral Stationary Phase

6.1	Introduction of Zafirlukast and survey of analytical methods	377-381
6.2	Development and validation of a novel HPLC method for the Separation of meta and para Isomers of Zafirlukast Using a Chiral Stationary phase.	382-422
6.3	Stability study of Zafirlukast bulk drug as per ICH Conditions (Q1AR2)	423-424
6.4	Summary and Conclusions.	424-427

CONTENTS (Contd.,)

o Page No

Chapter 7: Chiral Separation of (R,R)-Tadalafil and Its Enantiomer in Bulk Drug Samples and Pharmaceutical Dosage Forms by Chiral RP-LC

7.1	Introduction of Tadalafil and survey of analytical methods	428-430
7.2	Development and validation of a novel chiral RP-LC method for the separation of (R, R)-Tadalafil and its enantiomer.	430-463
7.3	Analysis of Tadalafil drug substance stability samples	464
7.4	Summary and Conclusions.	464-467
	Summary	468-490
	List of Publications : Appendix-1	